This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via Google Scholar Google Scholar Articles by Clark, W. M. Search for Related Content PubMed PubMed Citation Articles by Clark, W. M. Pubmed/NCBI databases Substance via MeSH Medline Plus Health Information Stroke Related Collections Acute Cerebral Hemorrhage Genetics of Stroke Related Article

(Stroke. 2005;36:1919.)
© 2005 American Heart Association, Inc.

Editorial Comment

Adiponectin

Spectator or Player?

Wayne M. Clark, MD

Oregon Stroke Center, Oregon Health Sciences University, Portland, Oregon

Key Words: inflammation • risk factors

An extract of the first 250 words of the full text is provided, because this article has no abstract.

Despite efforts at controlling traditional risk factors, stroke remains a devastating and all-too-common disease. Identifying new markers for patients at higher risk of stroke would aid in future risk factor management as well as potentially offering new venues for preventive therapies. In this issue of Stroke, Efstathiou et al¹ report on a highly significant inverse relation between adiponectin levels and subsequent 5-year mortality. Adiponectin, a recently discovered cytokine, has previously been theorized to be involved in the development of atherosclerotic disease.² Adiponectin appears to have both anti-inflammatory and antiatherogenic properties, and as such, it was expected that there would be an inverse relation between the serum level of adiponectin and subsequent cerebrovascular mortality. In their study, Efstathiou et al confirm this inverse relation, finding that patients with adiponectin levels in the lowest tertile had a 92.8% 5-year mortality compared with a 10.5% mortality in patients with adiponectin levels in the highest tertile.¹ This corresponds to an 8-fold increase in risk for individuals with low adiponectin levels compared with those with the highest tertile of adiponectin levels. Similar results with adiponectin have been seen in cardiovascular disease. In a case-control analysis from the Health Professionals Follow-up Study, among the 18 225 men without cardiovascular disease at baseline, those in the highest quintile of adiponectin level had a significantly reduced risk for myocardial infarction (relative risk [RR], 0.39; 95% confidence interval, 0.23 to 0.64; P for trend <0.001) compared with in the lowest quintile of adiponectin level.³

The results of this . . . [Full Text of this Article]

Related Article:

Plasma Adiponectin Levels and Five-Year Survival After First-Ever Ischemic Stroke

Stamatis P. Efstathiou, Dimitrios I. Tsioulos, Aphrodite G. Tsiakou, Yannis E. Gratsias, Angelos V. Pefanis, and Theodore D. Mountokalakis
Stroke 2005 36: 1915-1919. [Abstract] [Full Text] [PDF]